Mårten Fryknäs

Kort presentation

Publikationer

Urval av publikationer

• Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin (2017)
• Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype (2017)
• Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects (2016)
• Iron chelators target both proliferating and quiescent cancer cells (2016)
• Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition (2016)
• Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids (2016)
• Detection of cell aggregation and altered cell viability by automated label-free video microscopy (2015)
• Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs (2015)
• Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia (2015)
• In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index (2015)
• Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs (2015)
• The anticancer activity of the DUB inhibitor b-AP15 is associated with accumulation of proteasome bound ubiquitin and oxidative stress (2015)
• Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics (2015)
• Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer (2015)
• Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter (2014)
• Label free high throughput screening for apoptosis inducing chemicals using time-lapse microscopy signal processing (2014)
• Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress (2014)
• AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia (2014)
• Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia (2014)
• Identification of an inhibitor of the ubiquitin-proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function (2014)
• A spheroid-based screen identifies mitochondrial targeting as a promising strategy for cancer treatment and drug repositioning (2014)
• Elevation of Proteasomal Substrate Levels Sensitizes Cells to Apoptosis Induced by Inhibition of Proteasomal Deubiquitinases (2014)
• The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death (2014)
• Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments (2014)
• Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system (2013)
• Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance (2013)
• Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells (2013)
• Cell crowding results in accumulation of interferon-stimulated genes independently of STAT1 (2013)
• Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer (2013)
• Effects of hypoxia on human cancer cell line chemosensitivity (2013)
• The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo (2013)
• Association of interferon stimulated genes and IRF9 upregulation with drug resistance in multicellular spheroids and monolayer cells upon crowding (2013)
• Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro (2013)
• Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma (2012)
• Inhibition of proteasome deubiquitinating activity as a new cancer therapy (2011)
• Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids (2011)
• Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment (2011)
• Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia (2011)
• Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP) (2011)
• Novel activity of acriflavine against colorectal cancer tumor cells (2011)
• Stathmin as a Marker for Malignancy in Pheochromocytomas (2010)
• Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors (2010)
• Polycomb target genes are silenced in multiple myeloma (2010)
• High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation (2010)
• Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters (2009)
• Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs (2009)
• In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency (2007)
• STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines (2007)
• Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells (2007)
• Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model (2006)
• Molecular markers for discrimination of benign and malignant follicular thyroid tumors (2006)
• Screening of an annotated compound library for drug activity in a resistant myeloma cell line (2006)
• Improved variance estimation of classification performance via reduction of bias caused by small sample size (2006)
• Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles (2005)

Senaste publikationer

• OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids (2024)
• Exploratory insights from the immuno-oncology hollow fiber assay (2024)
• Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs (2024)
• Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients (2023)
• Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma (2023)

Alla publikationer

Artiklar

• OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids (2024)
• Exploratory insights from the immuno-oncology hollow fiber assay (2024)
• Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs (2024)
• Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients (2023)
• Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma (2023)
• Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death (2023)
• Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells (2022)
• Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival (2022)
• Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma (2022)
• Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model (2022)
• Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes (2021)
• Conditions for maintenance of hepatocyte differentiation and function in 3D cultures (2021)
• A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer (2021)
• Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway (2020)
• Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide (2020)
• Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. (2020)
• Descriptive Proteome Analysis to Investigate Context-Dependent Treatment Responses to OXPHOS Inhibition in Colon Carcinoma Cells Grown as Monolayer and Multicellular Tumor Spheroids (2020)
• Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition (2019)
• The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation (2017)
• Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. (2017)
• Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin (2017)
• Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity (2017)
• Targeting tumor cells based on Phosphodiesterase 3A expression (2017)
• Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype (2017)
• Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects (2016)
• Iron chelators target both proliferating and quiescent cancer cells (2016)
• Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition (2016)
• Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids (2016)
• Detection of cell aggregation and altered cell viability by automated label-free video microscopy (2015)
• Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs (2015)
• Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia (2015)
• In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index (2015)
• Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs (2015)
• The anticancer activity of the DUB inhibitor b-AP15 is associated with accumulation of proteasome bound ubiquitin and oxidative stress (2015)
• Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics (2015)
• Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer (2015)
• Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter (2014)
• Label free high throughput screening for apoptosis inducing chemicals using time-lapse microscopy signal processing (2014)
• Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress (2014)
• AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia (2014)
• Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia (2014)
• Identification of an inhibitor of the ubiquitin-proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function (2014)
• A spheroid-based screen identifies mitochondrial targeting as a promising strategy for cancer treatment and drug repositioning (2014)
• Elevation of Proteasomal Substrate Levels Sensitizes Cells to Apoptosis Induced by Inhibition of Proteasomal Deubiquitinases (2014)
• The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death (2014)
• Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments (2014)
• Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments (2014)
• Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system (2013)
• Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance (2013)
• Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells (2013)
• Cell crowding results in accumulation of interferon-stimulated genes independently of STAT1 (2013)
• Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer (2013)
• Effects of hypoxia on human cancer cell line chemosensitivity (2013)
• The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo (2013)
• Association of interferon stimulated genes and IRF9 upregulation with drug resistance in multicellular spheroids and monolayer cells upon crowding (2013)
• Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro (2013)
• Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma (2012)
• The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy (2012)
• Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system (2012)
• Inhibition of proteasome deubiquitinating activity as a new cancer therapy (2011)
• Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids (2011)
• Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment (2011)
• Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia (2011)
• Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP) (2011)
• Novel activity of acriflavine against colorectal cancer tumor cells (2011)
• Stathmin as a Marker for Malignancy in Pheochromocytomas (2010)
• Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors (2010)
• Polycomb target genes are silenced in multiple myeloma (2010)
• High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation (2010)
• The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan (2010)
• Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters (2009)
• Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs (2009)
• Gene expression signature-based chemcial genomics and activity pattern in a panel of tumour cell lines propose linalyl acetate as a protein kinase/NF-κB inhibitor (2008)
• In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency (2007)
• STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines (2007)
• Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells (2007)
• Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model (2006)
• Molecular markers for discrimination of benign and malignant follicular thyroid tumors (2006)
• Screening of an annotated compound library for drug activity in a resistant myeloma cell line (2006)
• Improved variance estimation of classification performance via reduction of bias caused by small sample size (2006)
• Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles (2005)
• The hollow fiber assay for modeling quiescent cancer cells in vitro and in vivo 
• Paired glioblastoma cell cultures of the fluorescent bulk tumor and non-fluorescent tumor margin display differential phenotypes and cell states across patients
• Drug combination screening in multicellular tumor spheroids identifies synthetic lethalities in quiescent cancer cells